LEXARIA AND NEUTRISCI ANNOUNCE SUCCESSFUL CANNABINOID
TABLET DEVELOPMENT AND POSITIVE RESULTS FROM INITIAL HUMAN
OBSERVATIONAL TRIALS.
Kelowna, BC January 19, 2017 - InvestorsHub NewsWire -
Lexaria Bioscience Corp. (OTCQB:LXRP)
(CSE:LXX)
(the Company or Lexaria) and NeutriSci International Inc. (the
"Company" or "NeutriSci") (TSX-V: NU,
Frankfurt-1N9) are pleased to announce the successful development
and initial trial of the industrys first zero-sugar cannabinoid /
pterostilbene edible tablet utilizing both Neutriscis and Lexarias
proprietary and patented technologies.
Neutriscis proprietary pterostilbene tablet formula was used to
produce the worlds first pterostilbene / cannabidiol (CBD) rapid
melt edible product offering the benefits of Lexarias patented CBD
conjugation technology. The market-ready tablet offers improvements
in taste, rapidity of onset, and strength of effect due to greater
bioavailability, as had been originally hypothesized.
After trial batch formulation and manufacturing was completed,
observational human tests supported that the user will experience
the effects faster and last longer while utilizing smaller amounts
of cannabinoid than competing products. The above noted benefits
offer manufacturing efficiencies over competing products, thus
potentially increasing comparative profitability.
NeutriSci and Lexaria confirm the companies expect to officially
bind the JV agreement to market and commercialize a line of edible
products using CBD derived from full spectrum hemp oil, which is
federally legal in the United States, to be followed by
tetrahydrocannabinol (THC) versions through distribution programs
with both existing and planned new strategic partners. With
successful first-stage formulation and human evaluation completed,
the companies expect to conclude a working JV structure as soon as
possible to financially capitalize on this unique opportunity.
This joint venture is a demonstration of the rapid innovation
occurring in the cannabis industry, commented Chris Bunka, CEO of
Lexaria Bioscience. We are excited to work with NeutriSci; to
combine both technology and form factor to develop healthy
cannabinoid products to be sold within NeutriScis international
distribution network.
We are very pleased with the results of this product formulation
and observational trial, as the initial results have be invaluable
in helping NeutriSci open dialogue with several of the worlds
largest CBD manufactures and distributors, commented Glen Rehman,
President of NeutriSci International. The idea to use our
sublingual tablet and form factor to create a new line of
zero-sugar and dose-controlled cannabinoid edible products will
become a reality.
Following the recent approvals for recreational use in certain
US states, Industry researchers have reported that the legal
cannabis market could exceed $20 Billion by 2020.
About Lexaria
Lexaria Bioscience Corp. is a food biosciences company with a
proprietary technology for improved delivery of bioactive
compounds. The Companys lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested
cannabinoids, while also masking taste. This technology promotes
healthy ingestion methods, lower overall dosing and higher
effectiveness in active molecule delivery. The Companys technology
is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for
Tetrahydrocannabinol (THC), other psychoactive cannabinoids,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
www.lexariabioscience.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation
of nutraceutical products. Established in 2009, NeutriSci has
focused on the development of several breakthrough nutraceutical
products with an initial focus on areas such as heart and
cholesterol health, sleep deprivation therapies, immune defense as
well as men's prostate and sexual health. NeutriSci continues to
build strong relationships and distribution channels for its
BluScience and NeuEnergy products with retailers throughout the
United States. NeutriSci is focusing efforts in strengthening
sustainable sales models with Convenience, Chain Drug, and Mass
Market and Supermarket retailers.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The
Company makes forward-looking public statements concerning its
expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements,
including but not limited to: that the market-ready tablet offers
improvements in taste, rapidity of onset, and strength of effect
due to greater bioavailability, that the user will experience the
effects faster and last longer while utilizing smaller amounts of
cannabinoids than competing products, or that any JV agreement to
market and commercialize a line of edible products using CBD
derived from full spectrum hemp oil, or from tetrahydrocannabinol
will ever be entered. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current
information and involve a number of risks and uncertainties, and
there can be no assurance that other factors will not affect the
accuracy of such forward-looking statements. Access to capital, or
lack thereof, is a major risk and there is no assurance that the
Company will be able to raise required working capital. Factors
which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to,
government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent
applications and approval process and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that any license agreement,
corporate activity in the hemp oil sector, or alternative health
businesses will provide any benefit to Lexaria, or that the Company
will experience any growth through participation in these sectors
or as a result of the granted patent. There is no assurance that
existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance
that Lexarias technology will deliver any improvement in taste or
bioavailability with any reliability nor across any product
category. There is no assurance that any planned corporate
activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any hemp
oil or cannabinoid-based product will promote, assist, or maintain
any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any
treaty will result in the award of an actual patent; nor that an
award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any of Lexarias
postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or
in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria Energy Foods and ViPovaTM
products are not intended to diagnose, treat, cure or prevent any
disease.
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.